Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of NALIRIFOX for locally advanced pancreatic cancer
ChiCTR2400089619Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan, fluorouracil, folinic acid and oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Surgical conversion rate. Started Sep 2024; status: recruiting.
02
Drugs
nanoliposomal irinotecanfluorouracilfolinic acidoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400089619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089619.